Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34 + hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma-Reference-Cited by-同舟云学术

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34 + hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

Published:2013-09-09 Issue:12 Volume:88 Page:1017-1023
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Micallef Ivana N.¹,Stiff Patrick J.²,Stadtmauer Edward A.³,Bolwell Brian J.⁴,Nademanee Auayporn P.⁵,Maziarz Richard T.⁶,Partisano Angela M.⁷,Marulkar Sachin⁸,DiPersio John F.⁹

Affiliation:

1. Mayo ClinicRochester Minnesota

2. Loyola UniversityChicago Illinois

3. University of PennsylvaniaPhiladelphia Pennsylvania

4. Cleveland ClinicCleveland Ohio

5. City of HopeDuarte California

6. Oregon Health and Science UniversityPortland Oregon

7. Sanofi OncologyCambridge Massachusetts

8. Genzyme, a Sanofi companyCambridge Massachusetts

9. Washington UniversitySt. Louis Missouri

Publisher

Wiley